MCID: PHS001
MIFTS: 41

Phosphorus Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Phosphorus Metabolism Disease

MalaCards integrated aliases for Phosphorus Metabolism Disease:

Name: Phosphorus Metabolism Disease 12 15
Phosphorus Metabolism Disorders 44 73
Disorder of Phosphorus Metabolism 12
Phosphorus Metabolism Disorder 12
Phosphorus Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2485
ICD9CM 35 275.3
MeSH 44 D010760
NCIt 50 C97095
UMLS 73 C0031707

Summaries for Phosphorus Metabolism Disease

MalaCards based summary : Phosphorus Metabolism Disease, also known as phosphorus metabolism disorders, is related to autosomal recessive hypophosphatemic rickets and hypophosphatemic rickets, autosomal dominant. An important gene associated with Phosphorus Metabolism Disease is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Parathyroid hormone synthesis, secretion and action. The drugs Calcium Carbonate and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Phosphorus is a chemical element with symbol P and atomic number 15. As an element, phosphorus exists in... more...

Related Diseases for Phosphorus Metabolism Disease

Diseases related to Phosphorus Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 autosomal recessive hypophosphatemic rickets 30.2 DMP1 FGF23 PHEX
2 hypophosphatemic rickets, autosomal dominant 30.1 FGF23 GALNT3 PHEX SLC34A3
3 vitamin d-dependent rickets, type 2a 29.4 CYP27B1 VDR
4 hypophosphatemic rickets with hypercalciuria, hereditary 26.2 CYP27B1 DMP1 FGF23 GALNT3 KL PHEX
5 hypophosphatemic rickets, x-linked dominant 25.8 CYP27B1 DMP1 FGF23 KL PHEX PTH
6 tracheal calcification 10.7 FGF23 KL
7 opsismodysplasia 10.6 FGF23 PHEX
8 hereditary hypophosphatemic rickets 10.5 SLC34A1 SLC34A3
9 impaired renal function disease 10.5 FGF23 PTH
10 tumoral calcinosis, hyperphosphatemic, familial, 1 10.5 FGF23 GALNT3 KL
11 arterial calcification of infancy 10.4 FGF23 GALNT3 PHEX
12 hypocalciuric hypercalcemia, familial, type iii 10.4 CASR PTH
13 hyperostosis 10.4 FGF23 GALNT3 KL
14 hypoparathyroidism, familial isolated 10.4 CASR PTH
15 urinary system disease 10.4 FGF23 KL PTH
16 hypocalciuric hypercalcemia, familial, type ii 10.4 CASR PTH
17 familial hypocalciuric hypercalcemia 10.3 CASR PTH
18 hypoparathyroidism 10.3 CASR FGF23 PTH
19 metaphyseal chondrodysplasia, jansen type 10.2 FGF23 PTH
20 familial tumoral calcinosis 10.2 FGF23 GALNT3 KL PHEX
21 enthesopathy 10.2 DMP1 FGF23 PHEX
22 calcinosis 10.1 FGF23 GALNT3 KL PHEX
23 pseudopseudohypoparathyroidism 10.1 GNAS PTH STX16
24 spondylosis 10.1 KL PTH VDR
25 pseudohypoparathyroidism, type ib 10.1 GNAS PTH STX16
26 metal metabolism disorder 10.1 GNAS PTH STX16
27 osteitis fibrosa 10.1 CASR GNAS PTH
28 pulmonary alveolar microlithiasis 10.1 FGF23 PTH SLC34A1 SLC34A3
29 pseudohypoparathyroidism 10.1 GNAS PTH STX16
30 albright's hereditary osteodystrophy 10.0 GNAS STX16
31 hypercalcemia, infantile, 1 10.0 CASR PTH VDR
32 nephrolithiasis 10.0 CASR SLC34A1 SLC34A3
33 hypophosphatasia, adult 10.0
34 acid phosphatase deficiency 10.0
35 hypophosphatasia, infantile 10.0
36 hypophosphatasia, childhood 10.0
37 hypophosphatasia 10.0
38 prenatal benign hypophosphatasia 10.0
39 parathyroid adenoma 9.9 CASR PTH VDR
40 multiple endocrine neoplasia, type i 9.9 CASR GNAS PTH
41 hypercalciuria, absorptive, 2 9.9 CASR SLC34A3 VDR
42 oncogenic osteomalacia 9.9 DMP1 FGF23 PHEX PTH
43 uremia 9.9 CASR PTH VDR
44 idiopathic hypercalciuria 9.9 CASR SLC34A3 VDR
45 caffey disease 9.9 FAM20C GALNT3
46 nephrolithiasis, calcium oxalate 9.9 CASR SLC34A1 VDR
47 raine syndrome 9.8 DMP1 FAM20C FGF23
48 calciphylaxis 9.8 CASR FGF23 PTH VDR
49 parathyroid gland disease 9.8 CASR FGF23 PTH VDR
50 renal osteodystrophy 9.8 CASR FGF23 PTH VDR

Comorbidity relations with Phosphorus Metabolism Disease via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Phosphorus Metabolism Disease:



Diseases related to Phosphorus Metabolism Disease

Symptoms & Phenotypes for Phosphorus Metabolism Disease

MGI Mouse Phenotypes related to Phosphorus Metabolism Disease:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 CYP27B1 DMP1 FAM20C FGF23 GALNT3 GNAS
2 homeostasis/metabolism MP:0005376 10.28 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
3 cellular MP:0005384 10.25 CASR CYP27B1 DMP1 FAM20C GALNT3 GNAS
4 behavior/neurological MP:0005386 10.22 STX16 VDR CASR CYP27B1 FAM20C GNAS
5 cardiovascular system MP:0005385 10.21 KL PTH STX16 VDR CYP27B1 DMP1
6 hematopoietic system MP:0005397 10.2 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
7 craniofacial MP:0005382 10.19 CYP27B1 DMP1 FAM20C GALNT3 GNAS KL
8 endocrine/exocrine gland MP:0005379 10.16 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
9 immune system MP:0005387 10.14 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
10 digestive/alimentary MP:0005381 10.13 CASR FAM20C FGF23 GALNT3 KL PHEX
11 limbs/digits/tail MP:0005371 10.02 CYP27B1 DMP1 FAM20C FGF23 GALNT3 GNAS
12 adipose tissue MP:0005375 9.97 KL PHEX STX16 CYP27B1 GNAS
13 renal/urinary system MP:0005367 9.93 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
14 integument MP:0010771 9.91 CASR CYP27B1 FGF23 GALNT3 GNAS KL
15 hearing/vestibular/ear MP:0005377 9.88 FAM20C GNAS KL PHEX VDR
16 muscle MP:0005369 9.8 CASR CYP27B1 GALNT3 GNAS KL SLC34A1
17 reproductive system MP:0005389 9.5 CYP27B1 FAM20C FGF23 GALNT3 KL SLC34A1
18 skeleton MP:0005390 9.47 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3

Drugs & Therapeutics for Phosphorus Metabolism Disease

Drugs for Phosphorus Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
2
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 62-54-4
3
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
4
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
6
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 1,Phase 2 59-67-6 938
7
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 1,Phase 2 98-92-0 936
8
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
9
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable 32222-06-3 134070 5280453
10
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
11 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
12 Antimetabolites Phase 4,Phase 1,Phase 2
13 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
18 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
19 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Nicotinic Acids Phase 4,Phase 1,Phase 2
21 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable
23 Vitamin B Complex Phase 4,Phase 1,Phase 2
24 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
25 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
26 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Ferric Compounds Phase 4,Phase 3,Phase 2
28 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
29 Ergocalciferols Phase 4,Phase 3,Not Applicable
30 Vasoconstrictor Agents Phase 4,Not Applicable
31 Folate Nutraceutical Phase 4,Phase 1,Phase 2
32 Vitamin B3 Nutraceutical Phase 4,Phase 1,Phase 2
33 Vitamin B9 Nutraceutical Phase 4,Phase 1,Phase 2
34 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
35 Calciferol Nutraceutical Phase 4,Phase 3,Not Applicable
36 Vitamin D2 Nutraceutical Phase 4,Phase 3,Not Applicable
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 1406-16-2
38 Calcimimetic Agents Phase 3,Phase 1,Not Applicable
39 Cinacalcet Hydrochloride Phase 3,Phase 1,Not Applicable
40 Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
41 Hormones Phase 3,Phase 1,Phase 2,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
43 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
44 Mitogens Phase 3,Phase 2,Phase 1,Not Applicable
45 Bile Acids and Salts Phase 3,Phase 1
46 Antibodies Phase 3,Phase 2
47 Antibodies, Monoclonal Phase 3,Phase 2
48 Immunoglobulin G Phase 3,Phase 2
49 Immunoglobulins Phase 3,Phase 2
50
Chitosan Approved, Nutraceutical Phase 2,Not Applicable 9012-76-4 71853

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
4 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
5 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Recruiting NCT03256838 Phase 4 Ferric Citrate
6 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
7 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
8 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Not yet recruiting NCT03079869 Phase 4 Ferric Citrate
9 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease Not yet recruiting NCT03466983 Phase 4 Iron Isomaltoside;Ferric Carboxymaltose
10 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
11 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
12 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
13 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
14 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
15 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
16 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
17 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
18 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
19 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
20 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
21 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
22 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
23 EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) Completed NCT00211978 Phase 3 calcium acetate;placebo
24 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
25 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01554982 Phase 3 ferric citrate
26 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
27 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
28 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
29 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
30 An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis Completed NCT00681941 Phase 3 Sevelamer carbonate (Renvela®)
31 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
32 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
33 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
34 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
35 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo
36 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
37 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
38 Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets Completed NCT01237288 Phase 3 Z-521
39 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
40 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Completed NCT00417612 Phase 3 Paricalcitol
41 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Recruiting NCT03427125 Phase 3 Tenapanor;Placebo;Sevelamer Carbonate
42 An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia Recruiting NCT02688764 Phase 3 PA21 (Velphoro®);Calcium Acetate (Phoslyra®)
43 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China Recruiting NCT03001011 Phase 3 Placebo;Sevelamer Carbonate (GZ419831)
44 Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets Recruiting NCT03581591 Phase 3
45 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04) Recruiting NCT03238911 Phase 3 Iron isomaltoside (Monofer);Ferric carboxymaltose
46 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05) Recruiting NCT03237065 Phase 3 Iron Isomaltoside (Monofer);Ferric carboxymaltose
47 Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study Active, not recruiting NCT01578200 Phase 3 Lanthanum Carbonate;Calcium Carbonate
48 Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) Active, not recruiting NCT02915705 Phase 3 oral phosphate;active vitamin D
49 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02537431 Phase 3
50 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Active, not recruiting NCT02526160 Phase 3

Search NIH Clinical Center for Phosphorus Metabolism Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: phosphorus metabolism disorders

Genetic Tests for Phosphorus Metabolism Disease

Anatomical Context for Phosphorus Metabolism Disease

MalaCards organs/tissues related to Phosphorus Metabolism Disease:

41
Kidney, Bone

Publications for Phosphorus Metabolism Disease

Variations for Phosphorus Metabolism Disease

Expression for Phosphorus Metabolism Disease

Search GEO for disease gene expression data for Phosphorus Metabolism Disease.

Pathways for Phosphorus Metabolism Disease

GO Terms for Phosphorus Metabolism Disease

Cellular components related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.35 GALNT3 GNAS PHEX SLC34A1 STX16
2 apical plasma membrane GO:0016324 9.02 CASR GNAS KL SLC34A1 SLC34A3

Biological processes related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.86 DMP1 FAM20C FGF23 SLC34A1
2 calcium ion transport GO:0006816 9.82 CASR CYP27B1 VDR
3 cellular calcium ion homeostasis GO:0006874 9.78 CASR PTH VDR
4 ossification GO:0001503 9.77 CASR DMP1 SLC34A1
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.76 FGF23 GALNT3 KL
6 bone mineralization GO:0030282 9.66 CYP27B1 PHEX
7 response to cadmium ion GO:0046686 9.66 PTH SLC34A1
8 calcium ion homeostasis GO:0055074 9.65 CYP27B1 KL
9 decidualization GO:0046697 9.65 CYP27B1 VDR
10 positive regulation of bone mineralization GO:0030501 9.65 FAM20C KL PTH
11 response to lead ion GO:0010288 9.64 PTH SLC34A1
12 regulation of bone mineralization GO:0030500 9.64 CYP27B1 FGF23
13 obsolete positive regulation of cAMP biosynthetic process GO:0030819 9.63 GNAS PTH
14 positive regulation of keratinocyte differentiation GO:0045618 9.63 CYP27B1 VDR
15 biomineral tissue development GO:0031214 9.63 DMP1 FAM20C PHEX
16 energy reserve metabolic process GO:0006112 9.62 GNAS KL
17 response to growth hormone GO:0060416 9.62 PHEX SLC34A1
18 response to magnesium ion GO:0032026 9.61 FGF23 SLC34A1
19 response to vitamin D GO:0033280 9.61 CYP27B1 PHEX PTH
20 phosphate ion transport GO:0006817 9.59 SLC34A1 SLC34A3
21 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
22 vitamin D metabolic process GO:0042359 9.58 CYP27B1 FGF23 VDR
23 sodium-dependent phosphate transport GO:0044341 9.57 SLC34A1 SLC34A3
24 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.55 FGF23 KL
25 skeletal system development GO:0001501 9.55 FAM20C GNAS PHEX PTH VDR
26 phosphate ion homeostasis GO:0055062 9.54 FGF23 SLC34A1
27 cellular response to vitamin D GO:0071305 9.54 CASR FGF23 PHEX
28 dentinogenesis GO:0097187 9.52 FAM20C SLC34A1
29 vitamin D catabolic process GO:0042369 9.51 CYP27B1 FGF23
30 cellular response to parathyroid hormone stimulus GO:0071374 9.5 FGF23 PHEX SLC34A1
31 response to sodium phosphate GO:1904383 9.49 FGF23 PHEX
32 cellular phosphate ion homeostasis GO:0030643 9.43 FGF23 SLC34A1 SLC34A3
33 response to parathyroid hormone GO:0071107 9.13 GNAS PTH SLC34A1
34 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 9.26 FGF23 KL
2 sodium:phosphate symporter activity GO:0005436 9.16 SLC34A1 SLC34A3
3 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.96 SLC34A1 SLC34A3
4 vitamin D binding GO:0005499 8.62 KL VDR

Sources for Phosphorus Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....